VRDN
Viridian Therapeutics, Inc.
Price Chart
Latest Quote
$18.03
+0.00 (+0.00%)
Current Price
| Previous Close | $18.03 |
| Open | $17.69 |
| Day High | $18.24 |
| Day Low | $17.54 |
| Volume | 2,075,725 |
Stock Information
| Shares Outstanding | 110.43M |
| Total Debt | $53.35M |
| Cash Equivalents | $762.18M |
| Revenue | $70.92M |
| Net Income | $-303.27M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.99B |
| EPS (TTM) | $-3.35 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.28B |
| Sales | $70.92M |
| Income | $-303.27M |
| Book/sh | $4.92 |
| Cash/sh | $6.90 |
| Employees | 252 |
Financial Ratios
| Quick Ratio | 14.71 |
| Current Ratio | 15.15 |
| Debt/Eq | 8.39 |
Returns & Margins
| ROA | -33.25% |
| ROE | -58.14% |
| Operating Margin | -82389.36% |
Ownership
| Insider Ownership | 0.14% |
| Institutional Ownership | 111.43% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.85 |
| P/S | 28.07 |
| P/B | 3.67 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $36.12 |
Technical Indicators
| SMA20 | $18.58 |
| SMA50 | $17.46 |
| SMA200 | $24.09 |
| RSI | 50.86 |
| ATR | 0.9673 |
| Shares Float | 97.76M |
| Short Float | 16.29% |
| Short Ratio | 7.56 |
| Volatility | 0.90 |
| Rel Volume | 0.81 |
Performance History
| Week | -8.66% |
| Month | +12.83% |
| Quarter | +22.99% |
| 6 Months | -46.63% |
| YTD | -41.23% |
| Year | +7.39% |
| 3 Years | -10.30% |
| 5 Years | +1.35% |
| 10 Years | -81.36% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $18.03 | 2,101,686 |
| 2026-07-16 | $18.03 | 2,097,300 |
| 2026-07-15 | $19.06 | 1,578,500 |
| 2026-07-14 | $19.08 | 1,140,800 |
| 2026-07-13 | $18.99 | 1,198,600 |
| 2026-07-10 | $19.74 | 1,431,800 |
| 2026-07-09 | $20.20 | 2,002,600 |
| 2026-07-08 | $19.86 | 1,720,500 |
| 2026-07-07 | $20.47 | 3,477,300 |
| 2026-07-06 | $18.99 | 1,725,600 |
| 2026-07-02 | $19.40 | 1,950,100 |
| 2026-07-01 | $18.48 | 3,267,000 |
| 2026-06-30 | $18.37 | 3,455,600 |
| 2026-06-29 | $18.79 | 7,604,600 |
| 2026-06-26 | $17.90 | 5,787,300 |
| 2026-06-25 | $17.39 | 1,878,200 |
| 2026-06-24 | $17.32 | 1,269,000 |
| 2026-06-23 | $17.28 | 1,666,200 |
| 2026-06-22 | $17.63 | 2,549,200 |
| 2026-06-18 | $16.63 | 4,032,000 |
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
đ° Latest News
Lumvoaâs Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)
Insider Monkey âĸ 2026-07-15T14:01:48Z
Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich?
Simply Wall St. âĸ 2026-07-15T12:24:01Z
Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today
Simply Wall St. âĸ 2026-07-15T05:10:14Z
âStay Investedâ: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market
TipRanks âĸ 2026-07-14T17:55:00Z
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone
Insider Monkey âĸ 2026-07-06T17:21:41Z
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Zacks âĸ 2026-07-01T14:41:00Z
Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says
MT Newswires âĸ 2026-06-30T15:53:22ZViridian may have edge over Amgen in eye drug showdown, analysts argue
BioPharma Dive âĸ 2026-06-30T11:33:00Z
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes for Renewed US-Iran Diplomacy
MT Newswires âĸ 2026-06-29T12:56:24ZComcast, Viridian Therapeutics jump premarket; Doximity slips
Investing.com âĸ 2026-06-29T12:09:07Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $70,849,000 | $302,000 | $314,000 | $1,772,000 |
| Operating Revenue | $70,849,000 | $302,000 | $314,000 | $1,772,000 |
| Expenses | ||||
| Interest Expense | $4,948,000 | $2,197,000 | $1,331,000 | $486,000 |
| Total Expenses | $434,244,000 | $299,337,000 | $254,764,000 | $136,076,000 |
| Other Income Expense | $-1,657,000 | $-314,000 | $-193,000 | - |
| Other Non Operating Income Expenses | $-1,657,000 | $-314,000 | $-193,000 | - |
| Net Non Operating Interest Income Expense | $22,451,000 | $29,400,000 | $16,909,000 | $4,430,000 |
| Interest Expense Non Operating | $4,948,000 | $2,197,000 | $1,331,000 | $486,000 |
| Operating Expense | $434,244,000 | $299,337,000 | $254,764,000 | $136,076,000 |
| General And Administrative Expense | $95,315,000 | $61,083,000 | $94,999,000 | $35,182,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-342,601,000 | $-269,949,000 | $-237,734,000 | $-129,874,000 |
| Net Interest Income | $22,451,000 | $29,400,000 | $16,909,000 | $4,430,000 |
| Interest Income | $27,399,000 | $31,597,000 | $18,240,000 | $4,916,000 |
| Normalized Income | $-342,601,000 | $-269,949,000 | $-237,734,000 | $-129,874,000 |
| Net Income From Continuing And Discontinued Operation | $-342,601,000 | $-269,949,000 | $-237,734,000 | $-129,874,000 |
| Total Operating Income As Reported | $-363,395,000 | $-299,035,000 | $-254,450,000 | $-134,304,000 |
| Net Income Common Stockholders | $-342,601,000 | $-269,949,000 | $-237,734,000 | $-129,874,000 |
| Net Income | $-342,601,000 | $-269,949,000 | $-237,734,000 | $-129,874,000 |
| Net Income Including Noncontrolling Interests | $-342,601,000 | $-269,949,000 | $-237,734,000 | $-129,874,000 |
| Net Income Continuous Operations | $-342,601,000 | $-269,949,000 | $-237,734,000 | $-129,874,000 |
| Pretax Income | $-342,601,000 | $-269,949,000 | $-237,734,000 | $-129,874,000 |
| Interest Income Non Operating | $27,399,000 | $31,597,000 | $18,240,000 | $4,916,000 |
| Operating Income | $-363,395,000 | $-299,035,000 | $-254,450,000 | $-134,304,000 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-3.32 | $-3.07 | $-5.31 | $-4.05 |
| Basic EPS | $-3.32 | $-3.07 | $-5.31 | $-4.05 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-337,193,000 | $-267,212,000 | $-235,881,000 | $-129,133,000 |
| Reconciled Depreciation | $460,000 | $540,000 | $522,000 | $255,000 |
| EBITDA (Bullshit earnings) | $-337,193,000 | $-267,212,000 | $-235,881,000 | $-129,133,000 |
| EBIT | $-337,653,000 | $-267,752,000 | $-236,403,000 | $-129,388,000 |
| Diluted Average Shares | $84,803,355 | $67,885,831 | $44,755,475 | $32,087,293 |
| Basic Average Shares | $84,803,355 | $67,885,831 | $44,755,475 | $32,087,293 |
| Diluted NI Availto Com Stockholders | $-342,601,000 | $-269,949,000 | $-237,734,000 | $-129,874,000 |
| Research And Development | $338,929,000 | $238,254,000 | $159,765,000 | $100,894,000 |
| Selling General And Administration | $95,315,000 | $61,083,000 | $94,999,000 | $35,182,000 |
| Other Gand A | $95,315,000 | $61,083,000 | $94,999,000 | $35,182,000 |
| Total Unusual Items | - | - | - | - |
| Total Unusual Items Excluding Goodwill | - | - | - | - |
Fetched: 2026-07-07
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $722,167,000 | $671,639,000 | $442,022,000 | $395,064,000 |
| Total Assets | $899,418,000 | $742,403,000 | $490,424,000 | $435,091,000 |
| Total Non Current Assets | $5,185,000 | $3,942,000 | $3,946,000 | $3,918,000 |
| Other Non Current Assets | $1,536,000 | $501,000 | $604,000 | $982,000 |
| Current Assets | $894,233,000 | $738,461,000 | $486,478,000 | $431,173,000 |
| Other Current Assets | $19,581,000 | $20,877,000 | $9,006,000 | $6,521,000 |
| Cash Cash Equivalents And Short Term Investments | $874,652,000 | $717,584,000 | $477,370,000 | $424,550,000 |
| Cash And Cash Equivalents | $212,382,000 | $99,594,000 | $102,827,000 | $155,579,000 |
| Receivables | - | $0 | $102,000 | $102,000 |
| Other Receivables | - | - | $102,000 | $102,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $50,693,000 | $21,095,000 | $21,048,000 | $5,258,000 |
| Long Term Debt And Capital Lease Obligation | $49,940,000 | $20,582,000 | $20,205,000 | $4,645,000 |
| Long Term Debt | $49,940,000 | $20,582,000 | $20,205,000 | $4,645,000 |
| Current Debt And Capital Lease Obligation | $753,000 | $513,000 | $843,000 | $613,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $177,251,000 | $70,764,000 | $48,402,000 | $40,027,000 |
| Total Non Current Liabilities Net Minority Interest | $106,555,000 | $22,890,000 | $21,767,000 | $6,678,000 |
| Other Non Current Liabilities | $2,341,000 | $2,308,000 | $989,000 | $1,172,000 |
| Derivative Product Liabilities | $20,030,000 | $0 | - | - |
| Non Current Deferred Liabilities | $34,244,000 | $0 | $573,000 | $861,000 |
| Current Liabilities | $70,696,000 | $47,874,000 | $26,635,000 | $33,349,000 |
| Current Deferred Liabilities | $367,000 | $288,000 | $288,000 | $288,000 |
| Payables And Accrued Expenses | $49,919,000 | $36,435,000 | $14,891,000 | $27,576,000 |
| Interest Payable | $385,000 | $154,000 | $154,000 | $39,000 |
| Payables | $8,683,000 | $2,143,000 | $2,239,000 | $14,234,000 |
| Accounts Payable | $8,683,000 | $2,143,000 | $2,239,000 | $14,234,000 |
| Other Current Liabilities | - | $100,000 | $100,000 | $100,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $590,111,000 | $482,754,000 | $235,506,000 | $252,917,000 |
| Preferred Stock Equity | $132,056,000 | $188,885,000 | $206,516,000 | $142,147,000 |
| Total Equity Gross Minority Interest | $722,167,000 | $671,639,000 | $442,022,000 | $395,064,000 |
| Stockholders Equity | $722,167,000 | $671,639,000 | $442,022,000 | $395,064,000 |
| Gains Losses Not Affecting Retained Earnings | $447,000 | $-10,000 | $338,000 | $-390,000 |
| Other Equity Adjustments | $447,000 | $-10,000 | $338,000 | $-390,000 |
| Retained Earnings | $-1,338,458,000 | $-995,857,000 | $-725,908,000 | $-488,174,000 |
| Other | ||||
| Ordinary Shares Number | $101,826,500 | $80,994,046 | $53,986,112 | $41,305,947 |
| Share Issued | $101,826,500 | $80,994,046 | $53,986,112 | $41,305,947 |
| Tangible Book Value | $590,111,000 | $482,754,000 | $235,506,000 | $252,917,000 |
| Invested Capital | $640,051,000 | $503,336,000 | $255,711,000 | $257,562,000 |
| Working Capital | $823,537,000 | $690,587,000 | $459,843,000 | $397,824,000 |
| Capital Lease Obligations | $753,000 | $513,000 | $843,000 | $613,000 |
| Total Capitalization | $772,107,000 | $692,221,000 | $462,227,000 | $399,709,000 |
| Additional Paid In Capital | $1,927,104,000 | $1,477,811,000 | $960,536,000 | $741,067,000 |
| Capital Stock | $133,074,000 | $189,695,000 | $207,056,000 | $142,561,000 |
| Common Stock | $1,018,000 | $810,000 | $540,000 | $414,000 |
| Preferred Stock | $132,056,000 | $188,885,000 | $206,516,000 | $142,147,000 |
| Non Current Deferred Revenue | $34,244,000 | $0 | $573,000 | $861,000 |
| Current Deferred Revenue | $367,000 | $288,000 | $288,000 | $288,000 |
| Current Capital Lease Obligation | $753,000 | $513,000 | $843,000 | $613,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $19,657,000 | $10,638,000 | $10,513,000 | $4,772,000 |
| Current Accrued Expenses | $41,236,000 | $34,292,000 | $12,652,000 | $13,342,000 |
| Net PPE | $3,649,000 | $3,441,000 | $3,342,000 | $2,936,000 |
| Accumulated Depreciation | $-1,216,000 | $-1,266,000 | $-1,049,000 | $-2,004,000 |
| Gross PPE | $4,865,000 | $4,707,000 | $4,391,000 | $4,940,000 |
| Leases | $271,000 | $254,000 | $670,000 | $1,113,000 |
| Other Properties | $3,678,000 | $3,346,000 | $2,815,000 | $2,770,000 |
| Machinery Furniture Equipment | $916,000 | $1,107,000 | $906,000 | $1,057,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $662,270,000 | $617,990,000 | $374,543,000 | $268,971,000 |
| Dueto Related Parties Non Current | - | - | - | - |
Fetched: 2026-07-07
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-276,886,000 | $-232,830,000 | $-185,068,000 | $-94,635,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-276,391,000 | $-232,319,000 | $-184,170,000 | $-93,838,000 |
| Cash Flow From Continuing Operating Activities | $-276,391,000 | $-232,319,000 | $-184,170,000 | $-93,838,000 |
| Operating Gains Losses | $700,000 | $449,000 | $182,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-495,000 | $-511,000 | $-898,000 | $-797,000 |
| Investing Cash Flow | $-37,563,000 | $-228,651,000 | $-94,252,000 | $-115,126,000 |
| Cash Flow From Continuing Investing Activities | $-37,563,000 | $-228,651,000 | $-94,252,000 | $-115,126,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $352,197,000 | $478,661,000 | $201,261,000 | $335,874,000 |
| Financing Cash Flow | $426,742,000 | $457,737,000 | $225,670,000 | $322,244,000 |
| Cash Flow From Continuing Financing Activities | $426,742,000 | $457,737,000 | $225,670,000 | $322,244,000 |
| Net Other Financing Charges | $30,880,000 | $-26,942,000 | $-12,315,000 | $-22,510,000 |
| Net Preferred Stock Issuance | $0 | $25,001,000 | $76,192,000 | $44,000,000 |
| Preferred Stock Issuance | $0 | $25,001,000 | $76,192,000 | $44,000,000 |
| Net Common Stock Issuance | $352,197,000 | $453,660,000 | $125,069,000 | $291,874,000 |
| Common Stock Issuance | $352,197,000 | $453,660,000 | $125,069,000 | $291,874,000 |
| Other | ||||
| Issuance Of Debt | $28,875,000 | $0 | $15,000,000 | $5,000,000 |
| Interest Paid Supplemental Data | $2,150,000 | $1,820,000 | $886,000 | $293,000 |
| End Cash Position | $212,382,000 | $99,594,000 | $102,827,000 | $155,579,000 |
| Beginning Cash Position | $99,594,000 | $102,827,000 | $155,579,000 | $42,299,000 |
| Changes In Cash | $112,788,000 | $-3,233,000 | $-52,752,000 | $113,280,000 |
| Proceeds From Stock Option Exercised | $14,790,000 | $6,018,000 | $21,724,000 | $3,880,000 |
| Net Issuance Payments Of Debt | $28,875,000 | $0 | $15,000,000 | $5,000,000 |
| Net Long Term Debt Issuance | $28,875,000 | $0 | $15,000,000 | $5,000,000 |
| Long Term Debt Issuance | $28,875,000 | $0 | $15,000,000 | $5,000,000 |
| Net Investment Purchase And Sale | $-37,068,000 | $-228,140,000 | $-93,354,000 | $-114,329,000 |
| Sale Of Investment | $542,208,000 | $466,928,000 | $314,526,000 | $108,935,000 |
| Purchase Of Investment | $-579,276,000 | $-695,068,000 | $-407,880,000 | $-223,264,000 |
| Net PPE Purchase And Sale | $-495,000 | $-511,000 | $-898,000 | $-797,000 |
| Purchase Of PPE | $-495,000 | $-511,000 | $-898,000 | $-797,000 |
| Change In Working Capital | $23,031,000 | $9,598,000 | $-9,425,000 | $15,962,000 |
| Change In Payables And Accrued Expense | $22,769,000 | $21,264,000 | $-7,318,000 | $19,240,000 |
| Change In Accrued Expense | $16,207,000 | $21,337,000 | $4,722,000 | $7,716,000 |
| Change In Payable | $6,562,000 | $-73,000 | $-12,040,000 | $11,524,000 |
| Change In Account Payable | $6,562,000 | $-73,000 | $-12,040,000 | $11,524,000 |
| Change In Prepaid Assets | $262,000 | $-11,666,000 | $-2,107,000 | $-3,339,000 |
| Other Non Cash Items | $4,474,000 | $997,000 | $6,785,000 | $264,000 |
| Stock Based Compensation | $44,303,000 | $42,150,000 | $67,172,000 | $19,765,000 |
| Amortization Of Securities | $-6,758,000 | $-15,655,000 | $-11,490,000 | $-210,000 |
| Depreciation Amortization Depletion | $460,000 | $540,000 | $522,000 | $255,000 |
| Depreciation And Amortization | $460,000 | $540,000 | $522,000 | $255,000 |
| Gain Loss On Investment Securities | $700,000 | - | - | - |
| Net Income From Continuing Operations | $-342,601,000 | $-269,949,000 | $-237,734,000 | $-129,874,000 |
| Change In Other Working Capital | - | $-288,000 | $-288,000 | $-288,000 |
| Change In Receivables | - | $102,000 | $0 | $349,000 |
| Gain Loss On Sale Of PPE | - | $449,000 | $1,000 | $0 |
| Sale Of PPE | - | - | $0 | $0 |
| Repayment Of Debt | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Net Business Purchase And Sale | - | - | - | - |
| Sale Of Business | - | - | - | - |
Fetched: 2026-07-07